Public health responses to the COVID-19 pandemic have reaped adverse physical, psychological, social and economic effects, with older adults disproportionally affected. Psychological consequences of the pandemic include fear, worry and anxiety. COVID-19 fear may impact individuals' mitigation behaviours, influencing their willingness to (re)engage in health, social and economic behaviours. This study seeks (1) to develop a robust and evidence-based questionnaire to measure the prevalence of COVID-19 fear among older adults (aged ≥50) in Scotland and (2) to examine the impact of COVID-19 fear on the willingness of older adults to (re)engage across health, social and economic domains as society adjusts to the 'new normal' and inform policy and practice.

Thematic Analysis

Worry

Delphi Method

Qualitative property

10.1136/bmjopen-2022-061427

Cite

Citations (1)

Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients

Biological Psychiatry (2010)

Roy H. Perlis Bonnie A. Fijal Sweta Dharia Alexandra N. Heinloth John P. Houston

Escitalopram

Serotonin reuptake inhibitor

10.1016/j.biopsych.2009.12.010

Cite

Citations (86)

Cognition: language, concepts, and problems

Elsevier eBooks (1985)

John P. Houston Helen L. Bee David C. Rimm

10.1016/b978-0-12-573946-7.50010-8

Cite

Citations (0)

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

Human Psychopharmacology Clinical and Experimental (2008)

David H. Adams Sandra Close Mark W. Farmen AnnCatherine M. Downing Alan Breier

Abstract Objective To test association of dopamine receptor D3 (DRD‐3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods Eighty‐eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser‐9‐gly (rs6280) and 23 other polymorphisms within the DRD‐3 gene. Allelic association of clinical response (mean baseline‐ to‐endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance. Results Ser‐9‐gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks ( p = 0.021). This association was most notable for improvement in positive symptoms ( p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%; p = 0.033). DRD‐3 polymorphisms in disequilibrium with ser‐9‐gly were also significantly associated with greater positive symptom improvement ( p = 0.0009–0.021), and one not in complete linkage disequilibrium, with lesser improvement ( p = 0.027). Conclusions Gly/gly DRD‐3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser‐9‐gly genotypes in patients treated with olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.

Linkage Disequilibrium

10.1002/hup.930

Cite

Citations (39)

A Unified Test for the Copyright Protection of the User Interface to Computer Programs

Duquesne Law Review (1993)

John P. Houston

Interface (matter)

Source

Cite

Citations (0)